Can-Fite BioPharma (CANF) Equity Average (2026)

Can-Fite BioPharma (CANF) has 14 years of Equity Average data on file, last reported at $5.2 million in Q2 2026.

• For the quarter ending Q2 2026, Equity Average fell 13.68% year-over-year to $5.2 million; the trailing twelve-month figure through Jun 2026 stood at $5.2 million (down 13.68% YoY), and the FY2025 full-year result was $5.5 million, down 5.57% from the prior year.
• Equity Average was $5.2 million for Q2 2026 at Can-Fite BioPharma, down from $6.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $13.2 million in Q1 2022 to a low of $4.0 million in Q4 2024.
• A 5-year average of $7.0 million and a median of $6.1 million in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 100.78% in 2022 and slumped 50.9% in 2023, its largest moves.
• Can-Fite BioPharma's Equity Average stood at $5.9 million in 2022, then slipped by 3.55% to $5.7 million in 2023, then tumbled by 31.04% to $4.0 million in 2024, then soared by 54.88% to $6.1 million in 2025, then fell by 14.78% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $5.2 million in Q2 2026, $6.1 million in Q4 2025, and $6.1 million in Q2 2025.